Bio-Path Holdings, Inc.

BPTH ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017
Operating Activities
Net Income $-9.9M $-16.1M $-13.9M $-10.4M $-10.9M $-8.6M $-8.6M $-7.0M
Depreciation & Amortization — — — — — — — —
Depreciation $53.0K $82.0K $88.0K $76.0K $72.0K $134.0K $265.0K $251.0K
Amortization — — — — — $0 $161.0K —
Stock-Based Compensation $566.0K $734.0K $851.0K $821.0K $577.0K $684.0K $554.0K $793.0K
Net Cash from Operating Activities $-10.6M $-11.5M $-15.1M $-9.9M $-11.0M $-8.4M $-6.1M $-8.0M
Investing Activities
Capital Expenditures — — $21.0K $70.0K — $0 $17.0K $538.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities — — $-21.0K $-70.0K — $0 $-17.0K $-538.0K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $10.7M $2.2M $1.7M $20.0M $4.3M $27.8M $1.2M $5.1M
Net Change in Cash $121.0K $-9.3M $-13.4M $10.0M $-6.7M $19.4M $-5.0M —
Free Cash Flow — — $-15.1M $-10.0M — $-8.4M $-6.1M $-8.5M
← Newer Page 1 of 2 Older →